Categories
Health

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is  a   biotech that has proved helpful diligently but unsuccessfully to develop an one-time therapy, variously named Pro 140, leronlimab, along with Vyrologix.

In development of this particular therapy, CytoDyn has cast its net wide and far both geographically and in terms of potential indications.

CytoDyn’s inventories of leronlimab are actually building up, whether they’ll ever be used is an open question.

While CYDY  has been dawdling, promote opportunities for leronlimab as being a combination treatment in the healing of multi-drug-resistant HIV happen to be closing.

I’m composing my fifteenth CytoDyn (OTCQB:CYDY) article on FintechZoom to celebrate the sale made of my past several shares. My first CytoDyn article, “CytoDyn: What to be able to Do When It’s Too Good In order to Be True?”, set away the following prediction:

Rather I expect it to turn into a serial disappointer. CEO Pourhassan offered such an extremely marketing picture in the Uptick Newswire job interview that I came away with a bad opinion of the business.

Irony of irony, my bad viewpoint of the business enterprise has grown steadily, yet the disappointment has not been financial. Two many years ago CytoDyn was trading <$1.00. On 2/19/20 as I create, it trades during $5.26; my closing transaction was on 2/11/21 > $6.00.

What manner of stock  is this that delivers a > six bagger yet still disappoints? Therein is the story; allow me to explain.

CytoDyn acquired its much-storied therapy (which I shall relate to as leronlimab) returned during 2012, announced as follows:

CytoDyn Inc…. has finished the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) looking for the CCR5 receptor for the treatment and reduction of HIV, coming from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is a late Stage II clinical development mAb with demonstrated anti-viral activity in HIV infected subjects. Today’s payment of $3.5 million transfers ownership of the technology and also linked intellectual property coming from Progenics to CytoDyn, as well as approximately 25 million mg of majority drug substance…. milestone payments upon commencement of a level III clinical trial ($1.5 huge number of) and the first new drug application approval ($five million), as well as royalty payments of 5 percent of net sales after commercialization.

Since that point in time, CytoDyn’s leading nous, Nader Pourhassan [NP] has turned this inauspicious acquisition into a springboard for CytoDyn to buy a market cap > $3.5 billion. It has done so in premium reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

As opposed to having a pipeline with many indications and numerous therapies, it’s this single therapies in addition to a “broad pipeline of indications” since it puts it. I call some pipelines, “pipedots.” In CytoDyn’s case it touts the leronlimab of its as a potentially advantageous therapy of dozens of indications.

Its opening banner on the website of its (below) shows an energetic business with diverse interests albeit centered on leronlimab, multiple illness types, multiple publications and multiple presentations.

Can all of it be smoke and mirrors? That’s a question I’ve been asking myself from the really beginning of my interest in this organization. Judging by the multiples of a huge number of several remarks on listings accessible via Seeking Alpha’s CytoDyn Summary page, I am far from alone in this particular question.

CytoDyn is a classic battleground, or even some could say cult stock. Its adherents are fiercely protective of the prospects of its, quick to label any bad opinions as scurrilous short-mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Leave a Reply

Your email address will not be published. Required fields are marked *